CME

Faculty: Michael Dolinger, MD, MBA

Faculty: Florence Odufalu, MD

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.

Faculty: Michael Dolinger, MD, MBA

Faculty: David T. Rubin, MD

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.

Faculty: Michael Dolinger, MD, MBA

Faculty: David T. Rubin, MD

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.

Faculty: Michael Dolinger, MD, MBA

Faculty: David T. Rubin, MD

This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.

Faculty: Jean Hoffman-Censits, MD

This 15-minute online CME activity reviews the clinical implications of the updated NCCN Guidelines for advanced urothelial carcinoma (aUC), with a focus on evolving first-line and subsequent treatment strategies. The program highlights the shift away from cisplatin eligibility as the primary determinant of frontline therapy selection and examines key clinical trial data that inform current practice. Participants will explore sequencing considerations following frontline therapy as well as the role of biomarker-directed therapies in later lines of care. The activity also emphasizes early recognition and management of treatment-related adverse events alongside strategies for dose modification and supportive care. Multidisciplinary coordination and shared decision-making are discussed as essential components of optimizing patient-centered care in aUC.

Faculty: Kathleen N. Moore, MD, MS

Dr. Kathleen Moore reviews the clinical significance of HER2 expression across diverse solid tumors and its role in guiding treatment decisions. She outlines HER2 testing methodologies, including immunohistochemistry (IHC), to identify patients with advanced solid tumors who may benefit from HER2-targeted antibody–drug conjugates (ADCs). Dr. Moore summarizes key data from trials such as DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 that supported tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) for previously treated metastatic HER2-positive (IHC 3+) solid tumors, along with strategies for proactive monitoring and management of ADC-associated adverse events.

Faculty: Adam J. Luginbuhl, MD

This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

Faculty: Adam J. Luginbuhl, MD

This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

Faculty: Jennifer Johnson, MD, PhD

This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.

Faculty: Jennifer Johnson, MD, PhD

This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and patient-centered discussions address how to identify appropriate candidates based on disease stage, PD-L1 expression, resectability, and overall fitness for multimodality therapy. The program reviews clinical evidence from perioperative studies, with emphasis on implications for integrating immunotherapy into curative-intent care. Practical considerations include surgical timing, multidisciplinary coordination, and management of immune-related adverse events. By illustrating shared decision-making and real-world communication between clinicians and patients, this program offers actionable insights into aligning treatment with patient goals while optimizing care across the perioperative continuum.